Results of the NICE fingolimod survey


"The results of this survey are not what I expected. I can only assume that the majority of you agree with NICE because fingolimod is not cost-effective?"

"I personally feel that fingolimod has several attributes that will make it a valuable addition to the DMTs we currently have available to treat RRMS."



"This survey had the largest number or responses to date. Thank you for your effort!"



CoI: Multiple

Other relevant posts on this blog:



05 Aug 2011
"While clinical trials have shown that fingolimod (also called Gilenya) can reduce the number of relapses in some people who have highly active relapsing-remitting multiple sclerosis (RRMS), it is unclear how much the ...


08 Jul 2011
What exactly are you planning on doing to change that Prof G? Having seen the Fingolimod corporate advert extolling its excellence I have to ask that if it is so effective why it is only approved for RRMS patients? ...
03 Jun 2011
What exactly are you planning on doing to change that Prof G? Having seen the Fingolimod corporate advert extolling its excellence I have to ask that if it is so effective why it is only approved for RRMS patients? ...